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Abstract
Background: A number of cytostatic agents have been investigated for the ability to reactivate latent viral
reservoirs, which is a major prerequisite for the eradication of HIV-1 infection. Two cytostatic bis(thiosemicarbazonate)
gold(III) complexes (designated 1 and 2) were tested for this potential in the U1 latency model of HIV-1 infection.
Methods: Cell viability in the presence or absence of 1 and 2 was determined using a tetrazolium dye and evidence of
reactivation was assessed by p24 antigen capture following exposure to a latency stimulant, phorbol myristate acetate
(PMA) and or test compounds. The latency reactivation mechanism was explored by determining the effect of the
complexes on protein kinase C (PKC), histone deacetylases (HDAC) and proinflammatory cytokine production.
Results: The CC50 of the complexes in U1 cells were 0.53 ± 0.12 μM for 1 and 1.0 ± 0.4 μM for 2. In the absence of PMA
and at non toxic concentrations of 0.2 and 0.5 μM, 1 and 2 significantly (p≤ 0.02) reactivated virus in U1 cells by 2.7
and 2.3 fold respectively. In comparison, a 2.6 fold increase (p = 0.03) in viral reactivation was observed for hydroxyurea
(HU), which was used as a cytostatic and latent HIV reactivation control. Viral reactivation was absent for the complexes
during co-stimulation with PMA indicating the lack of an additive effect between the chemicals as well as an absence
of inhibition of PMA induced HIV reactivation but for HU inhibition of the stimulant’s activity was observed (p = 0.01).
Complex 1 and 2 activated PKC activity by up to 32% (p < 0.05) but no significant inhibition of HDAC was observed.
Increases in TNF-α levels suggested that the reactivation of virus by the complexes may have been due to contributions
from the latter and the activation of PKC.
Conclusion: The ethyl group structural difference between 1 and 2 seems to influence bioactivity with lower active
concentrations of 1, suggesting that further structural modifications should improve specificity. The cytostatic effect of 1
and 2 and now HIV reactivation from a U1 latency model is consistent with that of the cytostatic agent, HU. These
findings suggest that the complexes have a potential dual (cytostatic and reactivation) role in viral “activation/elimination”.
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Background
Latent reservoirs of HIV result from the integration of
viral cDNA into the host cell genome [1]. These latent
reservoirs enable viral persistence even in the presence of
potent antiretroviral therapy [2-4] or immune responses
[1]. The latently infected cells are replication competent
following reactivation ([5] and thus lead to viral load
increases after highly active antiretroviral therapy (HAART)
interruption [6,7]. Reactivation of these reservoirs, while
maintaining HAART, is one approach that is being
considered for the elimination of latency and HIV infection
overall [8]. This approach which has been termed
“activation/elimination” aims to flush out latent virus by
inducing expression of viral proteins [9]. The high levels
of viral protein produced means viral cytopathic effect
increases and the virus becomes more visible to the
immune system such that cytotoxic CD8+ cells or adminis-
tered therapeutic agents become more effective.
Various small molecules reactivate latent virus through
different mechanisms [10]. Proinflammatory cytokines
such as interleukin (IL)-3, IL-6, and TNF-α are one such
group of molecules which activate latent infection
in vitro ([11]. Latent virus reactivation was first reported
for PMA in 1988 by Folks and his colleagues [12]. This
phorbol ester is also an inducer of monocyte differentiation
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[13,14] and of HIV production [15]. The induction of latent
virus production by PMA has been associated with the
endogenous production of proinflammatory cytokines
such as TNF-α [16]. Another phorbol ester, prostratin,
also reactivates latent virus and upregulates TNF-α
production [17]. Prostratin, like other PKC activators
induces virus from latency through the activation of
the transcription factor NF-κB [10]. Together with the
viral reactivating potential, prostratin also inhibits HIV
through the down-regulation of the CD4 coreceptor and
has been recommended as a potential inductive adjuvant
therapy in HAART because of these combined effects
[17]. Another group of compounds that reportedly
activate latent virus are HDAC inhibitors. These inhibitors
prevent HDAC from producing hypoacetylated nucleo-
somes at the HIV promoter, hence preventing latency [18].
In addition, cytostatic agents such as actinomycin D and
HU reactivate latently infected U1 cells and enhance viral
replication [19]. The mechanism of viral reactivation by
HU is not clear while actinomycin D has been reported to
reactivate virus by modulating cytokine production causing
increases in IL-6 and decreases in TNF-β [20]. HU is also
known to have anti-HIV effects as a result of its ability to
deplete intracellular pools of deoxynucleotide triphosphates
(dNTPs) which in turn inhibits viral DNA synthesis making
it a cytostatic agent [21-23]. The viral reactivating effect of
HU in conjunction with its HIV inhibiting ability suggests
that this chemical could also be part of an inductive
adjuvant therapy with HAART just like prostratin.
We previously reported the antiviral effect of two bis
(thiosemicarbazonate) gold(III) complexes (1 and 2) and
proposed that this effect was as a result of the cytostatic
abilities of these complexes [24]. Cytostatic complexes in
combination with directly antiviral drugs are proposed
as an alternative anti-viral treatment approach referred
to as virostatic cocktails [25,26]. Virostatic combinations
involving HU and didanosine have been shown to be
clinically effective [27-29] but toxicity concerns continue
to prevent wider usage. Because some cytostatic agents
also reactivate latent virus (HU and actinomycin D as
examples) the possibility that the cytostatic complexes
1 and 2, could also exert an effect on viral reactivation
existed and was explored here.
For this study, a promonocytic cell line (U1) which is
an in vitro model of postintegration latency [19] was used.
Postintegration latency unlike preintegration latency
occurs when the genome of a provirus is silenced
such that effective expression after integration into
the host cell genome is prevented [8]. PMA was used as a
stimulant for latent virus activation due to its effect on
the binding of NF-κB dependent transcription [30,31],
resulting in the transcription of viral genes. The complexes
reactivated latent virus at non toxic concentrations. This
reactivation appeared to be dependent on PKC activation
and to an extent on the endogenous production of TNF-α.
The complexes used in this study could form part of
virostatic cocktails and the concurrent reactivation of
latent HIV suggests that these complexes could potentially
be used in virus “activation/elimination” as a means of
flushing out latent HIV.
Methods
Compounds and gold complexes
The synthesis of the bis(thiosemicarbazonate) gold(III)
complexes (1 and 2) have previously been reported [24].
The gold(III) complexes have general formula; [Au(L)]Cl,
where L = L1, diacetyl-bis(N4-ethylthiosemicarbazone, L2,
diacetyl-bis(N4-methylthiosemicarbazone). L1 and L2 are
also known as the precursor compounds or ligands used
in synthesising 1 and 2 while HAuCl4.4H2O is the gold
starting material. Complex 1 differs from 2 by the
presence of an ethyl group in place of a methyl group
as shown in the molecular formulae in Figure 1. HU
was purchased from Sigma Aldrich (Missouri, USA). The
compounds and complexes were dissolved in DMSO
(vehicle) to 20 mg/mL and stored in single use aliquots
at −20°C before further dilution with culture media as
needed in the various assays to final DMSO concentration
of ≤0.6% (v/v).
Cells
The promonocytic U1 cell line [11] was obtained from
the AIDS Research and Reference Reagent Program,
NIAID, National Institute of Health (Rockville, MD). U1
cells are a subclone of U937 cells which are chronically
infected with HIV-1. CD4 levels are low and constitutive
Figure 1 Molecular structure of complexes 1 and 2 [24]. This figure is reproduced with permission from the Journal of Inorganic Biochemistry.
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expression of virus is minimal. The cells therefore re-
quire the use of stimulants such as the proinflammatory
cytokines of the IL family (IL-3, IL-6), TNF-α and granulo-
cyte colony-stimulating factor or PMA to stimulate virus
expression [11,12]. Generally, HIV replication from cell lines
and cells from HIV infected people require activation [32].
U1 cells were maintained at 1x105 cells/mL in RPM1 1640
containing 2 mM L glutamine (Sigma Aldrich, Missouri
USA), supplemented with 10% fetal bovine serum (Thermo
Scientific, HyClone®, UT, USA), 100 U/mL penicillin and
100 μg/mL streptomycin (Thermo Scientific, HyClone®, UT,
USA). The cells were subcultured every two days.
Effect of the complexes on the viability of U1 cells using
MTT
U1 cells (5x104 cells/mL) were treated with eight different
concentrations of L1, L2, 1, 2 as well as HAuCl4.4H2O
and HU ranging from 0.2-100 μM. An untreated vehicle
control sample contained cells and 0.6% DMSO, a cell only
control, and a blank control contained 0.6% DMSO only.
The cells were incubated for 72 h (37°C, 90% humidity, 5%
CO2) after which 140 μL of spent medium was discarded
and replaced with an equivalent amount of complete media
and 20 μL of 5 mg/mL MTT. The developed colour was
analysed after 2 h following solubilisation of the MTT
formazan product using acidified isopropanol. Absorbance
was measured at 550 nm and a reference wavelength of
690 nm on a Multiskan Ascent® spectrophotometer
(Labsystems, Helsinki, Finland). Cell viability was calculated
using the formula: (absorbance of sample - absorbance of
medium/ absorbance of vehicle control - absorbance of
medium) x 100. The vehicle (0.6%) control did not alter cell
viability and was similar to the cell only control. The CC50
of the complexes and ligands were graphically obtained
after generating a dose response curve using Graphpad
Prism® software (California, USA). An ordinary two way
analysis of variance (ANOVA) followed by a Tukey’s mul-
tiple comparison test was used in determining differences
between treatments and p < 0.05 was considered significant.
HIV-1 replication
In determining complex effect on HIV-1 replication,
two approaches were used. The first approach involved
determining the effect of the complexes on latent virus
reactivation in the absence of stimulant and the second in
the presence of stimulant mediated reactivation using
PMA (Sigma Aldrich (Missouri, USA). In both approaches,
latently infected U1 cells at 5 x104 cells/mL were treated
with non toxic concentrations of L1, L2, 1 and 2 for 72 h
(37°C, 5% CO2). In the co-stimulation study where com-
plex effect on PMA mediated reactivation of HIV was
sought, 3 nM of PMA was added to the test samples 6 h
post treatment. PMA also served as a control for reactiva-
tion. After the 72 h incubation, cell free supernatant was
collected and tested for p24 antigen levels using the
RETROtek p24 kit (ZeptoMetrix Corporation, New
York, USA) following the manufacturer’s instructions.
Viral reactivating mechanism
Effect of the complexes on HDAC and PKC activity
To determine the mechanism of viral reactivation,
complex effect on HDAC inhibition and PKC activation
was investigated. A fluorometric HDAC assay kit (Sigma,
MO, USA) was used and the assay performed according
to the manufacturer’s instructions. Trichostatin-A (TSA)
was used as a positive control for HDAC inhibition [33].
Other controls included substrate, a blank (buffer only)
and an untreated enzyme control. The% activity was
calculated using the formula: (test sample RFU-blank
RFU/untreated control RFU-blank RFU) x100) where
RFU = relative fluorescence units.
PKC was measured from cell lysates of U1 cells treated
with the complexes for 72 h (37°C, 5% CO2). Prostratin
was used as a control for PKC activation. The PKC
Kinase activity assay was obtained from Enzo Life Sciences
(NY, USA) and performed according to the manufacturer’s
instructions. Kinase activity was calculated using the
formula: (Test compound absorbance–Blank absorbance)/
(vehicle control absorbance-Blank absorbance) x 100.
Effect of complexes 1 and 2 on TNF-α production
The proinflammatory cytokine, TNF-α, stimulates the
HIV-1 long terminal repeat (LTR) through the activation
of NF-κB in both human CD4+ T cells and monocytes/
macrophages [7]. Stimulants such as PMA have been
reported to reactivate virus as a result of promoting
the endogenous production of TNF-α which in turn
stimulates the HIV-1 LTR. To determine if complexes
1 and 2 were associated with increases in TNF-α levels
and thus viral reactivation, a cytometric bead array kit
(CBA, BD BioSciences, California, USA) was used to
assess the content of this cytokine in the U1 culture
supernatants. The assay was performed according to
the manufacturer’s instructions.
Statistical analysis
Data analysis was performed using Graphpad Prism®
(California USA) and a Student’s t test for unpaired
observations. A p < 0.05 was considered significant. All
data are presented as mean ± SEM where n = 3-6.
Results and discussion
U1 cell viability studies
A dose response curve from 0.2 – 25 μM of the viability
of U1 cells was obtained for 1 and 2 and for the precursor
ligands, HAuCl4.4H2O, and HU from 0.8-100 μM
(Figure 2). The complexes were more toxic than the com-
plementary ligands and gold starting material (p < 0.05)
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with 50% cytotoxic concentrations (CC50s) of 0.53 ±
0.12 μM and 1.00 ± 0.4 μM for 1 and 2 respectively.
Ligands L1 and L2 as well as HU were non toxic with CC50
of > 100 μM while that of HAuCl4.4H2O was > 50 μM.
Considering that toxic concentrations could provide false
information on the effect of the complexes in the
other cell-based assays, only non toxic concentrations
were subsequently used. For complex 1, concentrations of
0.2 μM and lower were used while for 2, concentrations of
0.5 μM and lower were used since these resulted in more
than 85% cell viability.
Reactivation of latent HIV-1
For the activation studies, U1 cells were treated with
complex only or co-stimulated with complex and PMA.
Findings from these treatments are shown in Figure 3.
To easily differentiate the effect of the complexes in
each treatment type, the vehicle control and PMA
treated cells were represented as 100% in Figure 3A and B
respectively. For comparison of the differences between the
vehicle control, complex treated and complex plus PMA,
another representation of the data in Figure 3 is shown in
Additional file 1: Figure S2 for complexes 1 and 2.
In the absence of stimulant
The complexes were treated at three concentrations in a
pre-screen (at CC50 or below, Additional file 1: Figure S1);
complex 1 significantly reactivated viral production from
the U1 cells by 2.7 fold (p = 0.023) when tested at 0.2 μM
while complex 2 (0.5 μM), reactivated HIV replication by
2.3 fold (p = 0.005) when compared to untreated or cells
only control (Figure 3A). At 200 μM, HU, a cytostatic
agent used as a positive control, reactivated virus by 2.6
fold (p = 0.03). Complexes 1 and 2 were previously
reported as cytostatic [24] and now with the ability to
reactivate virus, have another activity in common with
HU although demonstrating this activity at much
lower concentrations. Ligands L1 and L2 had no
effect on viral reactivation supporting our findings
and previous reports for metal-based drugs that the metal
entity is important for bioactivity. Also as expected, the
gold starting material, HAuCl4.4H2O did not reactivate
virus, further supporting the role of ligand complexation
in metal-based drugs, as being activity enhancing [34].
The HIV-1 reactivation findings for these gold-based
complexes are also supported by those reported for
auranofin, another gold-based drug which induced HIV-1
reactivation from primary monocyte-derived macrophages
as reported in the Additional file one by Shytaj et al. [35].
PMA reactivated virus production from the U1 cells (7.8
fold increase, Figure 3A) when compared to the vehicle
control, confirming previous reports [12,17].
PMA co-stimulation
In the co-stimulation treatment, the expectation was
that the complexes would either synergistically reactivate
virus in concert with PMA or inhibit virus production
effected by the phorbol ester. For 1 and 2, neither a syner-
gistic reactivation nor inhibition of PMA mediated viral
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Figure 2 Effect of complex 1 and 2 and the associated ligands on U1 cell viability. A dose response curve was obtained for complexes
1 and 2 from 0.2-25 μM with CC50 values of 0.53 ± 0.12 and 1.00 ± 0.4 μM respectively. L1, L2 and HU were less toxic with CC50 > 100 μM while
that of the gold (synthesis) starting material, HAuCl4.4H2O was >50 μM. The numbers above the bar graphs are the CC50 values. # Two fold serial
dilutions from 100 down to 0.8 μM were performed. ****p < 0.0001, ***p = 0.0001, **p = 0.002.
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since no significant increases or decreases in percentage
reactivation was observed (Figure 3B and Additional file 1:
Figure S2). Synergistic activation has been defined as the
situation where the combination of two activators pro-
duces a level of activation that is greater than the sum of
the effects produced with the individual activators [36].
This type of activation is important as it makes it possible
to combine different latency activators to improve on the
effectiveness of viral reactivation [18]. PMA’s activation
of virus replication minimised the effects of all the treat-
ments, except for that of HU which at 200 μM, inhibited
p24 antigen production by 44% (p = 0.01, Figure 3B). This
finding is not surprising since HU has been reported to
inhibit HIV-1 LTR transactivation in the presence of both
TNF-α and PMA as stimulants [19,37]. According to
Calzado and his colleagues [37], this inhibition of PMA
mediated HIV-1 replication suggests that HU is capable of
inhibiting HIV by another mechanism, in addition to RNR
inhibition. HU inhibits activation mediated by PMA
and TNF-α, which are both transcriptional activators
but synergistically activates virus in the presence of the
posttranslationally active cytokine, IL-6, by causing
increases in Sp1 and Sp3 proteins which are involved in
the expression of HIV-1 LTR [19,38]. Considering that 1
and 2 did not inhibit viral production when co-stimulated
with PMA, it is possible that the mechanism of activation
is different from that of HU. Alternatively, it could be
a concentration dependent issue and because higher
concentrations of 1 and 2 were toxic to U1 cells, inhibition
at higher concentrations would not be of value.
The reactivation for the complexes is shown here for
the U1 promonocytic cell line model of latency as proof
of concept that the cytostatic compounds also reactivate
virus like HU. To have a better in vivo representation of
the potential of these complexes as latency reactivators,
a test on reactivation on T cells will be important since
HIV predominantly resides in resting memory CD4+ Tcells
[39]. Unfortunately, another gold-based drug, auranofin
was unable to activate latent HIV from primary CD4+ T
cells [40]. The possibility that this could be applicable for
complexes 1 and 2 which are also gold-based complexes
exists. That notwithstanding, the complexes could play a
role in reactivating virus from a subset of the immune
system cells and further confirmation in a monocyte-
derived macrophage cell line will be important in further
exploring this potential.
Viral reactivation mechanism
Complex effect on HDAC and PKC activity
Because HDAC plays a role in maintaining latency,
inhibitors of these enzymes reactivate latent virus. To
determine whether complex 1 and 2’s ability to reactivate
virus was as a result of inhibiting HDAC, the activity of
this enzyme in the presence of non-toxic concentrations
of the complexes was evaluated using a fluorometric assay.


















































































































































Figure 3 Complex 1 and 2 reactivate HIV replication in latently infected U1 cells. At non toxic concentrations of 0.2 and 0.5 μM viral p24
levels increased by 2.7 and 2.3 fold for complex 1 and 2 respectively (*p≤ 0.03) while 200 μM HU, which was included in the study as a cytostatic
positive control, reactivated latent virus by 2.6 fold (A). PMA (3 nM), which was used both as a positive control for virus activation and to monitor the
effect of the complexes on activated virus, significantly activated viral production (p = 0.01). HU also significantly (p = 0.01) inhibited PMA mediated
latency activation by 44% when compared to PMA treated cells only, an observation which was absent for 1 and 2 (B). The p24 levels for the vehicle
control and PMA treated cells are represented as 100% so that differences resulting from complex effects could easily be differentiated.
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activity when a cut-off of 50% inhibition was considered.
For 2, a 27.4% inhibition was not significant (p > 0.05).
TSA which was used as the positive control significantly
(p < 0.0005) inhibited HDAC by 103.7% (Figure 4A).
Another mechanism by which viral latency activators
function is by activating PKC. PKC activation by 1 and 2
significantly (p < 0.05) increased by 31.5 and 32.6% at 0.2
and 0.5 μM respectively compared to the vehicle only
which was the 100% reference (Figure 4B). Kinase activity
increased significantly by 80.3% for cells treated with
1 μg/mL of the positive control, prostratin.
These results indicate that PKC activation contributed
to the HIV-1 reactivation observed for complexes 1 and
2 from the latently infected U1 cells. While complexes
1 and 2, which are gold(III) thiosemicabazonate-based
are structurally different from the known PKC activators,
it is interesting to note that reactivation of HIV-1 is asso-
ciated to the activation of this enzyme. Interestingly, in
the co-stimulation studies with another PKC activator,
PMA, no significant differences in viral reactivation was
observed at the tested concentrations (Figure 3B and
Additional file 1: Figure S2). A co-stimulation study with
or without a PKC inhibitor should provide additional
mechanistic information.
For the HDAC assay, the observed 27.4% inhibition for
2, was not significant. The latter assay was not cell-based
and higher concentrations of the complexes did not
inhibit the enzyme (data not shown). Future studies to
confirm the absence of HDAC activity will include doing
the reactivation studies in the presence or absence of a
histone acetyltransferases (HAT) inhibitor. Considering
that the balance between protein acetylation and deacety-
lation controls several physiological and pathological
cellular processes, the inhibition of HAT and thus
alteration of the HAT/HDAC enzymes which maintain
this balance [41] should provide additional mechanistic
information. As part of continual investigations on the
functionality of these complexes in HIV reactivation, these
types of analysis will be considered.
Endogenous TNF-α production as viral reactivation
mechanism
Stimulants such as PMA are associated with stimulating
endogenous production of proinflammatory cytokines
such as TNF-α [16], which in turn stimulates the HIV-1
LTR leading to viral reactivation. In vitro stimulation
with TNF-α result in viral reactivation [11], further
supporting this. TNF-α has been implicated in the
immune disregulation observed in HIV since it promotes
systemic inflammation resulting in disease progression
in vivo [42] making it an important molecule in HIV
infection. To further probe the mechanism by which
complexes 1 and 2 reactivated virus, determination of
TNF-α production was performed using the BD BioSciences
(California, USA) CBA kit. The cytokines quantified by
the kit included IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ
and IL-17A. For the purposes of this study, the main
focus was on the endogenous production of TNF-α.
TNF-α levels were shown to increase by 9 fold for
complex 1 and 3 fold for complex 2 compared to the
vehicle control (Figure 5) while for PMA treated cells, the






































































































Figure 4 The effects of the complexes on HDAC and PKC activity. At a cut-off of ≥50% inhibition as inhibitory, complex 1 and 2 did not
appreciably inhibit HDAC. The positive control, TSA, inhibited the enzyme by 103.7% with a p value of <0.0001 (A). The enzyme control is
represented as 100% inhibition. In the PKC assay, significant increases in PKC activity of 31.5 (p = 0.033) and 32.7% (p = 0.036) were observed for
1 and 2 respectively compared to the untreated vehicle control (B) suggesting that reactivation was as a result of an effect on NF-κB. Prostratin,
a PKC activator caused significant increases in PKC of 80.3% (p = 0.02). The vehicle control sample is represented as 100% activity.
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2353.86 ± 204 pg/mL (648 fold). Although increases were
observed for 1, the findings were not statistically signifi-
cant (p > 0.05) suggesting that TNF-α stimulation might
only be playing a contributory role which together with
the increase in kinase activity resulted in HIV reactivation.
Complex 1’s effect on TNF-α was more elevated than
2 supporting the fact that reactivation of latent virus
induced by 1 exceeded that of 2.
At 200 μM, HU had no major effect on the production
of TNF-α and because this compound also had no effect
on PKC and HDAC, the mechanism by which HU reacti-
vates virus probably differs from that of the complexes. In
1997, Navarra and his colleagues reported HU as capable
of stimulating TNF-α production in vivo [43], and the lack
thereof in this in vitro set up means other necessary
factors required for an effect by HU on this cytokine, were
absent. The cytostatic compound actinomycin D reacti-
vates virus by modulating the cytokines IL-6 and TNF-β
[20]. IL-6 levels were not affected by either the complexes
or HU in our case. Complexes 1 and 2 also increased
TNF-α levels in peripheral blood mononuclear cells from
HIV negative donors (Additional file 1: Figure S3). This
indicates that the in vitro upregulation of TNF-α occurs
not only in the promonocytic U1 cell line but also ex vivo
in primary immune system cells.
Upregulation of proinflammatory cytokine production
by 1 and 2 (although not statistically significant) could
imply that these complexes might be reactivating virus
through a non specific mechanism, which is a concern with
most latency activating agents [18]. Such a nonspecific
mechanism might present these complexes as non selective
meaning structural modifications for improved efficacy is
needed. These modifications should also address the
toxicity issues associated with the complexes with
better targeting to latent reservoirs such as the use of
nanotechnology [44].
Cytostatic agents arrest the cell cycle but according to
Oguariri et al. [19], HU did not arrest U1 cells in the S
and G2/M phases of the cell cycle as expected. This
could be the reason why viral reactivation and hence
replication occurred since retrovirus replication depends
on cell cycling. Cell cycle analysis was performed for 1
and 2 and similarly to HU, cell cycle arrest of U1 cells
was absent in the S and G2/M phases (data not shown).
Conclusions
Inhibition of HIV by two bis(thiosemicabazonate) gold
(III) complexes (1 and 2) was previously shown to be as
a result of the cytostatic effects of the complexes as well
as the lowering of CD4+ cell numbers [24], a finding
also reported for HU [27-29]. Here we presented data
indicating that the complexes had another characteristic
that was similar to HU; viral reactivation potential,
(with 1 being more potent than 2 possibly due to the
ethyl group structural difference between the two). The
mechanism by which 1 and 2 triggered viral reactivation
in U1 cells was as a result of PKC activation (p < 0.05) with
a minimal contribution from the endogenous production
Figure 5 Effect of complex 1 and 2 on TNF-α production from U1 cells. Cell free supernatant from U1 cells treated with 1 and 2 was
analysed using the CBA kit technology. TNF-α levels were increased by 9 and 3 fold for 1 and 2 respectively. The observed visual differences
between treated and untreated cells was not statistically significant (p > 0.05) but could be contributing to the viral reactivation mechanism
observed. PMA was used as a positive control and significantly stimulated TNF-α (p = 0.004). The data is plotted on a log scale, n = 3.
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of TNF-α. Direct enzyme inhibition of HDAC was <50%.
Considering that prostratin reactivates virus by activating
PKC and at the same time upregulates TNF-α, the possibil-
ity that the complexes can do same exists. The increase in
the endogenous production of TNF-α by viral reactivating
agents like the phorbol esters, PMA and prostratin
was previously reported [16,17], and is confirmed here for
PMA. The concern that most effective latency activators
may cause generalised immune activation through the
induction of abundant proinflammatory cytokines since
the expression of HIV is closely linked to the activation
state of the host cell [18], could be a concern for these
complexes since this cytokine was minimally stimulated.
Like prostratin, the combined effects executed means the
complexes could eventually be recommended as inductive
adjuvant therapy in HAART [17].
The reactivation of latent HIV-1 by these complexes
are findings reported for the first time for metallo-
drugs that are also cytostatic (an indirect anti-viral
property). Kinase enzyme activation and to an extent,
endogenous TNF-α production were implicated in the
reactivation mechanism. The results obtained support
HIV-1 reactivation by the cytostatic complexes but
further studies to determine the exact mechanism of
reactivation of the dual (cytostatic and reactivation) role
the complexes could play in viral “activation/elimination”
is needed.
Additional file
Additional file 1: This file contains a graph with data on the dose
responsiveness of the reactivation effect caused by the complexes
as Figure S1. A figure representing data shown in Figure 3 of the main
manuscript is presented in another format in Figure S2. while the effect
of the complexes on endogenous production of TNF-α from PBMCs is
included as Figure S3.
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